Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial.

Saved in:
Bibliographic Details
Title: Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial.
Authors: Hecht JR; Division of Hematology/Oncology, David Geffen School of Medicine at University of California Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA., Park YS; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea., Tabernero J; Medical Oncology Department, Vall d'Hebron University Hospital and Institute of Oncology, Barcelona, Spain., Lee MA; School of Medicine, The Catholic University of Korea, Seoul, South Korea., Lee S; Division of Oncology/Hematology, Department of Internal Medicine, Korea University Anam Hospital, Seoul, South Korea., Virgili AC; Medical Oncology Department, IR SANT PAU, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain., Van den Eynde M; Department of Medical Oncology, Institut Roi Albert II, Cliniques Universitaires Saint-Luc, Institut de Recherche Clinique et Experimentale (Pole MIRO), Université Catholique de Louvain, Brussels, Belgium., Fontana E; Drug Development Unit, Sarah Cannon Research Institute, London, UK., Fakih M; Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Asghari G; Department of Medical Oncology, Bankstown Hospital, Bankstown, NSW, Australia., So J; Medical Oncology, Harbour Cancer and Wellness, Auckland, New Zealand., Stein A; Hematology-Oncology Practice Eppendorf, University Cancer Center, Hamburg, Germany., Dubreuil O; Medical Oncology Unit, Diaconesses-Croix St Simon Hospital, Paris, France., Bodnar L; Department of Oncology, Institute of Health Sciences, University of Siedlce, Siedlce, Poland., He CS; Exelixis, Alameda, CA, USA., Wang G; Exelixis, Alameda, CA, USA., Smith R; Exelixis, Alameda, CA, USA., Eng C; Department of Medicine, Division of Hematology and Oncology, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA., Saeed A; Department of Medicine, Division of Hematology and Oncology, University of Pittsburgh Medical Center and UPMC Hillman Cancer Center, Pittsburgh, PA, USA. Electronic address: saeeda3@upmc.edu.
Corporate Authors: STELLAR-303 study investigators
Source: Lancet (London, England) [Lancet] 2025 Nov 15; Vol. 406 (10517), pp. 2360-2370. Date of Electronic Publication: 2025 Oct 20.
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; Comparative Study
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1474-547X
DOI:10.1016/S0140-6736(25)02025-2